Csaba Földesi

Csaba Földesi

Auto-generated profile, based on publicly available information

Csaba Földesi

Gottsegen National Cardiovascular Center , Budapest

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
KCKyoung Ryul Julian Chun
Kyoung Ryul Julian Chun
KOKen Okumura
Ken Okumura
FSFernando Scazzuso
Fernando Scazzuso
YOYoung Keun On
Young Keun On
FKFred J. Kueffer
Fred J. Kueffer
CFCsaba Földesi
Csaba Földesi
Background: Cryoballoon ablation is a commonly used approach to treat patients with atrial fibrillation (AF).Objectives: Report on the safety and efficacy of cryoballoon ablation for the treatment of AF in the largest global cohort of cryoablated patients prospectively studied within a single registry.Methods: The Cryo AF Global Registry is a prospective, multi‐center registry. Patients with paroxysmal AF (PAF) or persistent AF (PsAF) were treated with the cryoballoon catheter according to routine practices at 93 sites across 36 countries. Primary efficacy endpoints included freedom from AF and freedom from AF/atrial flutter (AFL)/atrial tachycardia (AT) ≥30 seconds. The primary safety endpoint was serious device‐ or procedure‐related adverse events over 12 month follow‐up.Results: During this evaluation window, 2922 subjects completed an index cryoballoon procedure, and 1440 completed 12 month follow‐up. The cohort was 61 ± 12 years of age, 36.3% female, and 78.7% PAF. Serious device‐ and procedure‐related adverse event rates were 1.5% and 3.4%, respectively. Freedom from AF/AFL/AT after the 90 day blanking period was 86.4% (95% CI: 84.3%‐88.3%) in patients with PAF and 70.9% (95% CI: 64.6%‐76.4%) in patients with PsAF. Freedom from AF/AFL/AT in first‐line PAF and PsAF was 90.0% (95% CI: 86.4%‐92.7%) and 72.9% (95% CI: 58.6%‐83.0%) at 12 months, respectively.Conclusions: The Cryo Global AF Registry is the largest evaluation to demonstrate cryoablation is an efficient, safe, and effective treatment for patients with AF worldwide. Cryoablation was commonly used to treat patients prior to an AAD failure and may facilitate earlier therapy for patients on the AF disease continuum.

4 August 2025 in EP Europace
Verified
Journal Article
Open access
VTVassil Traykov
Vassil Traykov
HPHelmut Purerfellner
Helmut Purerfellner
HBHaran Burri
Haran Burri
CFCsaba Laszlo Foldesi
Csaba Laszlo Foldesi
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
JMJosé L Merino
José L Merino
The 2024 European Heart Rhythm Association (EHRA) Summit in Warsaw focused on the digital transformation of arrhythmia management, convening over 130 stakeholders from academia, industry, and policy. This review summarises the current state (in 2025) and future directions of digital health in arrhythmia care, including remote monitoring (RM) of cardiac implantable electronic devices (CIEDs), mobile health (mHealth), artificial intelligence (AI), and integration into the European Health Data Space (EHDS). RM has become central to CIED follow-up, improving outcomes and reducing healthcare use. However, challenges in reimbursement, workforce adaptation, and data interoperability persist. The absence of standardised data exchange between device vendors and healthcare systems has led to initiatives like the World Forum on CIED follow-up to develop interoperability standards. mHealth tools, including apps and wearable devices, offer accurate arrhythmia detection but face regulatory, digital literacy, and privacy barriers. The EHDS aims to enable cross-border data sharing for personalised care and real-world research, though implementation must address ethical, legal, and infrastructural issues. AI shows promise in prediction, monitoring, and data integration, but lacks standardised, transparent validation. The ESC-EHRA Atlas in Heart Rhythm Disorders supports structured data collection to harmonize and benchmark care across Europe. Overall, digital innovations, if coupled with regulatory alignment, interoperability standards, and equitable access, have the potential to shift arrhythmia management toward a more predictive, personalized, and efficient model of care.

21 December 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RRRoberto Rordorf
Roberto Rordorf
FSFernando Scazzuso
Fernando Scazzuso
KCKyoung Ryul Julian Chun
Kyoung Ryul Julian Chun
SKSurinder Kaur Khelae
Surinder Kaur Khelae
FKFred J. Kueffer
Fred J. Kueffer
TIthe Cryo AF Global Registry Investigators
the Cryo AF Global Registry Investigators
Background: Heart failure (HF) and atrial fibrillation (AF) often coexist; yet, outcomes of ablation in patients with AF and concomitant HF are limited. This analysis assessed outcomes of cryoablation in patients with AF and HF. Methods and Results: The Cryo AF Global Registry is a prospective, multicenter registry of patients with AF who were treated with cryoballoon ablation according to routine practice at 56 sites in 26 countries. Patients with baseline New York Heart Association class I to III (HF cohort) were compared with patients without HF. Freedom from atrial arrhythmia recurrence ≥30 seconds, safety, and health care utilization over 12‐month follow‐up were analyzed. A total of 1303 patients (318 HF) were included. Patients with HF commonly had preserved left ventricular ejection fraction (81.6%), were more often women (45.6% versus 33.6%) with persistent AF (25.8% versus 14.3%), and had a larger left atrial diameter (4.4±0.9 versus 4.0±0.7 cm). Serious procedure‐related complications occurred in 4.1% of patients with HF and 2.6% of patients without HF ( P =0.188). Freedom from atrial arrhythmia recurrence was not different between cohorts with either paroxysmal AF (84.2% [95% CI, 78.6–88.4] versus 86.8% [95% CI, 84.2–89.0]) or persistent AF (69.6% [95% CI, 58.1–78.5] versus 71.8% [95% CI, 63.2–78.7]) ( P =0.319). After ablation, a reduction in AF‐related symptoms and antiarrhythmic drug use was observed in both cohorts (HF and no‐HF), and freedom from repeat ablation was not different between cohorts. Persistent AF and HF predicted a post‐ablation cardiovascular rehospitalization ( P =0.032 and P =0.001, respectively). Conclusions: Cryoablation to treat patients with AF is similarly effective at 12 months in patients with and without HF. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02752737.

2 July 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
BMBéla Merkely
Béla Merkely
RHRobert HATALA
Robert HATALA
EMEperke Merkel
Eperke Merkel
MSMátyás Szigeti
Mátyás Szigeti
BVB Veres
B Veres
Annamária KosztinAnnamária Kosztin
Annamária Kosztin
Recommendations on cardiac resynchronization therapy (CRT) in patients with atrial fibrillation or flutter (AF) are based on less robust evidence than those in sinus rhythm (SR). We aimed to assess the efficacy of CRT upgrade in the BUDAPEST-CRT Upgrade trial population by their baseline rhythm. Heart failure patients with reduced ejection fraction (HFrEF) and previously implanted pacemaker (PM) or implantable cardioverter defibrillator (ICD) and ≥20% right ventricular (RV) pacing burden were randomized to CRT with defibrillator (CRT-D) upgrade (n = 215) or ICD (n = 145). Primary [HF hospitalization (HFH), all-cause mortality, or <15% reduction of left ventricular end-systolic volume] and secondary outcomes were investigated. At enrolment, 131 (36%) patients had AF, who had an increased risk for HFH as compared with those with SR [adjusted hazard ratio (aHR) 2.99; 95% confidence interval (CI) 1.26–7.13; P = 0.013]. The effect of CRT-D upgrade was similar in patients with AF as in those with SR [AF adjusted odds ratio (aOR) 0.06; 95% CI 0.02–0.17; P < 0.001; SR aOR 0.13; 95% CI 0.07–0.27; P < 0.001; interaction P = 0.29] during the mean follow-up time of 12.4 months. Also, it decreased the risk of HFH or all-cause mortality (aHR 0.33; 95% CI 0.16–0.70; P = 0.003; interaction P = 0.17) and improved the echocardiographic response (left ventricular end-diastolic volume difference −49.21 mL; 95% CI −69.10 to −29.32; P < 0.001; interaction P = 0.21). In HFrEF patients with AF and PM/ICD with high RV pacing burden, CRT-D upgrade decreased the risk of HFH and improved reverse remodelling when compared with ICD, similar to that seen in patients in SR. In AF patients CRT-D upgrade reduced the risk of mortality or HF hospitalization as compared with ICD, additionally echocardiographic parameters, symptoms, and NT-proBNP levels improved. However, the risk of HF hospitalization was higher in AF patients when compared with SR. AF, atrial fibrillation or flutter; aOR, adjusted odds ratio; aHR, adjusted hazard ratio; CI, confidence interval; CRT-D, cardiac resynchronization therapy with defibrillator; ICD, implantable cardioverter defibrillator; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVESV, left ventricular end-systolic volume; NT-proBNP, N-terminal pro b-type natriuretic peptide; PCI, percutaneous coronary intervention; PM, pacemaker; RV, right ventricular; SR, sinus rhythm.

28 February 2009 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
IKImre Kassai
Imre Kassai
CFCsaba Foldesi
Csaba Foldesi
székely andreaszékely andrea
székely andrea
TSTamas Szili-Torok
Tamas Szili-Torok

12 December 2023 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
DLDennis Lawin
Dennis Lawin
TLThorsten Lawrenz
Thorsten Lawrenz
KCK. R. Julian Chun
K. R. Julian Chun
HLHong Euy Lim
Hong Euy Lim
VOValentine Obidigbo
Valentine Obidigbo
TIthe Cryo AF Global Registry Investigators
the Cryo AF Global Registry Investigators
Background: Limited information is available on the safety and efficacy of cryoballoon ablation (CBA) in elderly patients with atrial fibrillation (AF). Moreover, global utilization of CBA in this population (≥ 80 years old) has not been reported. This study’s objectives were to determine the use, efficacy, and safety of CBA to treat octogenarians suffering from AF. Methods: In this sub-analysis of the Cryo Global Registry, 12-month outcomes of treating AF via CBA in octogenarians were compared to patients < 80 years old. Efficacy was evaluated as time to a ≥ 30 s atrial arrhythmia (AA) recurrence. Healthcare utilization was determined via repeat ablations and hospitalizations. Improvement upon disease burden was evaluated through patient reporting of symptoms and the EQ-5D-3L quality of life (QoL) survey. Results: The octogenarian cohort (n = 101) had a higher prevalence of females (51.5% vs 35.7%) and CHA2DS2-VASc scores (4.2 ± 1.3 vs 2.0 ± 1.5) compared to the control cohort (n = 1573, both p < 0.01). Even when adjusting for baseline characteristics and antiarrhythmic drug usage, freedom from AA recurrence at 12 months (80.6% vs 78.9%, HRadj:0.97 [95% CI:0.59–1.58], p = 0.90) was comparable between octogenarians and control, respectively. Similar serious adverse event rates were observed between octogenarians (5.0%) and control (3.2%, p = 0.38). The groups did not differ in healthcare utilization nor reduction of AF-related symptoms from baseline to follow-up, but both experienced an improvement in QoL at 12 months. Conclusions: Despite more age-related comorbidities, CBA is a safe and effective treatment for AF in octogenarians, with efficacy and adverse events rates akin to ablations performed in younger patients. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT02752737 Graphical